117 related articles for article (PubMed ID: 7576965)
1. Differentiation and prognosis of neuroblastoma in correlation to the expression of CD44s.
Terpe HJ; Christiansen H; Gonzalez M; Berthold F; Lampert F
Eur J Cancer; 1995; 31A(4):549-52. PubMed ID: 7576965
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors.
Combaret V; Lasset C; Frappaz D; Bouvier R; Thiesse P; Rebillard AC; Philip T; Favrot MC
Eur J Cancer; 1995; 31A(4):545-9. PubMed ID: 7576964
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of CD44s in human neuroblastic tumors: Moroccan experience and highlights on current data.
Tabyaoui I; Tahiri-Jouti N; Serhier Z; Bennani-Othmani M; Sibai H; Itri M; Benchekroun S; Zamiati S
Diagn Pathol; 2013 Feb; 8():39. PubMed ID: 23445749
[TBL] [Abstract][Full Text] [Related]
4. CD44s expression correlated with the International Neuroblastoma Pathology Classification (Shimada system) for neuroblastic tumours.
Munchar MJ; Sharifah NA; Jamal R; Looi LM
Pathology; 2003 Apr; 35(2):125-9. PubMed ID: 12745459
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma.
Combaret V; Gross N; Lasset C; Frappaz D; Beretta-Brognara C; Philip T; Beck D; Favrot MC
Eur J Cancer; 1997 Oct; 33(12):2101-5. PubMed ID: 9516862
[TBL] [Abstract][Full Text] [Related]
6. Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma.
Christiansen H; Sahin K; Berthold F; Hero B; Terpe HJ; Lampert F
Eur J Cancer; 1995; 31A(4):541-4. PubMed ID: 7576963
[TBL] [Abstract][Full Text] [Related]
7. [Expression of CD44-standard in 182 primary neuroblastomas].
Christiansen H; Terpe HJ; Gonzales M; Wenderhold S; Berthold F; Lampert F
Klin Padiatr; 1995; 207(4):219-21. PubMed ID: 7564156
[TBL] [Abstract][Full Text] [Related]
8. [CD44 expression: a new prognostic factor in neuroblastoma].
Combaret V; Lasset C; Bouvier R; Frappaz D; Thiesse P; Rebillard AC; Philip T; Favrot MC
Bull Cancer; 1995 Jan; 82(2):131-6. PubMed ID: 10846530
[TBL] [Abstract][Full Text] [Related]
9. CD44 expression and modulation on human neuroblastoma tumours and cell lines.
Gross N; Beck D; Beretta C; Jackson D; Perruisseau G
Eur J Cancer; 1995; 31A(4):471-5. PubMed ID: 7576948
[TBL] [Abstract][Full Text] [Related]
10. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma.
Kramer K; Cheung NK; Gerald WL; LaQuaglia M; Kushner BH; LeClerc JM; LeSauter L; Saragovi HU
Eur J Cancer; 1997 Oct; 33(12):2098-100. PubMed ID: 9516861
[TBL] [Abstract][Full Text] [Related]
11. CD44-high neural crest stem-like cells are associated with tumour aggressiveness and poor survival in neuroblastoma tumours.
Vega FM; Colmenero-Repiso A; Gómez-Muñoz MA; Rodríguez-Prieto I; Aguilar-Morante D; Ramírez G; Márquez C; Cabello R; Pardal R
EBioMedicine; 2019 Nov; 49():82-95. PubMed ID: 31685444
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of CD44s in renal cell carcinoma lacks independent prognostic significance.
Costa WH; Rocha RM; Cunha IW; Guimaraes GC; Zequi Sde C
Int Braz J Urol; 2012; 38(4):456-65. PubMed ID: 22951174
[TBL] [Abstract][Full Text] [Related]
13. CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation.
Gross N; Beretta C; Peruisseau G; Jackson D; Simmons D; Beck D
Cancer Res; 1994 Aug; 54(15):4238-42. PubMed ID: 7518353
[TBL] [Abstract][Full Text] [Related]
14. Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence.
Gilcrease MZ; Guzman-Paz M; Niehans G; Cherwitz D; McCarthy JB; Albores-Saavedra J
Cancer; 1999 Dec; 86(11):2320-6. PubMed ID: 10590373
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD44 variant proteins in adenocarcinoma of Barrett's esophagus and its relation to prognosis.
Böttger TC; Youssef V; Dutkowski P; Maschek H; Brenner W; Junginger T
Cancer; 1998 Sep; 83(6):1074-80. PubMed ID: 9740070
[TBL] [Abstract][Full Text] [Related]
16. Clinical relevance of TRKA expression on neuroblastoma: comparison with N-MYC amplification and CD44 expression.
Combaret V; Gross N; Lasset C; Balmas K; Bouvier R; Frappaz D; Beretta-Brognara C; Philip T; Favrot MC; Coll JL
Br J Cancer; 1997; 75(8):1151-5. PubMed ID: 9099963
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD44 and its isoforms in the fetal neuroblasts.
Kaya G; Laurini R; Chaubert P; Gross N
Appl Immunohistochem Mol Morphol; 2001 Jun; 9(2):180-4. PubMed ID: 11396637
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value and clinicopathological significance of CD44 expression in ovarian cancer: a meta-analysis.
Zhao L; Gu C; Huang K; Zhang Z; Ye M; Fan W; Han W; Meng Y
Arch Gynecol Obstet; 2016 Nov; 294(5):1019-1029. PubMed ID: 27300001
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
20. Expression of CD44s in human colorectal cancer.
Khoursheed M; Mathew TC; Makar RR; Sonia L; Abul H; Asfar S; Al-Sayer H; Dashti HM; Al-Bader A
Pathol Oncol Res; 2002; 8(3):170-4. PubMed ID: 12515996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
